<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
  <url><loc>https://liganx.com/</loc><lastmod>2026-08-26</lastmod><priority>1.0</priority></url>
  <url><loc>https://liganx.com/library</loc><lastmod>2026-08-26</lastmod><priority>0.8</priority></url>
  <url><loc>https://liganx.com/validation</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/mutation-docking-guide</loc><lastmod>2026-08-26</lastmod><priority>0.8</priority></url>
  <url><loc>https://liganx.com/about</loc><lastmod>2026-08-26</lastmod><priority>0.6</priority></url>
  <url><loc>https://liganx.com/contact</loc><lastmod>2026-08-26</lastmod><priority>0.5</priority></url>
  <url><loc>https://liganx.com/blog</loc><lastmod>2026-08-26</lastmod><priority>0.9</priority></url>
  <url><loc>https://liganx.com/privacy</loc><lastmod>2026-08-26</lastmod><priority>0.3</priority></url>
  <url><loc>https://liganx.com/terms</loc><lastmod>2026-08-26</lastmod><priority>0.3</priority></url>
  <url><loc>https://liganx.com/blog/acalabrutinib-venetoclax-fixed-duration-cll-amplify</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/akt1-e17k-capivasertib-pi3k-pathway</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/alk-g1202r-solvent-front-lorlatinib-docking</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/alk-g1202r-solvent-front-resistance</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/alk-l1196m-gatekeeper-crizotinib-resistance</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/alphafold-structures-for-docking</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ames-mutagenicity-structural-alerts-genotoxicity-prediction</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/aqueous-solubility-drug-discovery</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/bcr-abl-t315i-cml-resistance-ladder</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/bcr-abl-tki-landscape-imatinib-to-asciminib</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/blood-brain-barrier-cns-penetration-kinase-inhibitors</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/boltz2-cofolding-when-to-use</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/braf-class-2-3-non-v600-mutations</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/braf-v600e-melanoma-colorectal-paradox</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/btk-c481s-pirtobrutinib-reversible-binder</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/caco-2-permeability-intestinal-absorption-admet</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/cdk46-inhibitors-hr-positive-breast-cancer</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/consensus-scoring-docking-virtual-screening</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/covalent-docking-how-it-works</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/cryptic-allosteric-pockets-docking</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/cyp3a4-ddi-oncology-kinase-inhibitors</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ddg-vs-absolute-docking-scores</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/dfg-out-type-ii-kinase-inhibitors</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/dili-drug-induced-liver-injury-oncology</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/docking-search-box-grid-size-placement</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/egfr-c797s-osimertinib-resistance-fourth-generation</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/egfr-exon-19-deletions-nsclc</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/egfr-exon-20-insertions-amivantamab-sunvozertinib-zipalertinib</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/egfr-l858r-activating-mutation-nsclc</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/egfr-uncommon-mutations-g719x-l861q-s768i</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ensemble-docking-multiple-receptor-conformations</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/esr1-y537s-d538g-endocrine-resistance</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/fep-relative-binding-free-energy</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/flt3-aml-inhibitor-landscape</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/flt3-itd-d835y-aml-resistance</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/giredestrant-lidera-oral-serd-adjuvant-breast-cancer</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/her2-exon-20-insertions-zongertinib-nsclc</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/her2-positive-cancer-drug-landscape</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/herg-silent-killer-kinase-programs</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/idh1-r132h-glioma-aml-vorasidenib</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/induced-fit-docking-receptor-flexibility</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kit-d816v-systemic-mastocytosis-avapritinib</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kit-gist-resistance-ladder</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kras-g12c-clinical-landscape</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kras-g12d-pdac-drugging-the-bigger-cousin</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kras-g12r-pancreatic-cancer-pi3k-impaired</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kras-g12v-pan-ras-undruggable-frontier</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/kras-q61-mutations-codon-61</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ligand-efficiency-metrics-le-lle-lelp</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/lipophilicity-logp-logd-admet</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/met-d1228-y1230-resistance-type-i-met-inhibitors</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/met-exon-14-skipping-nsclc-capmatinib-tepotinib</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/metabolic-stability-intrinsic-clearance-microsomal-half-life</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/mm-gbsa-rescoring-docking-poses</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/oral-decitabine-cedazuridine-venetoclax-aml</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/p-glycoprotein-efflux-cns-penetration</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/pains-pan-assay-interference-compounds</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/pik3ca-e545k-e542k-helical-domain-mutations</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/pik3ca-h1047r-inavolisib-pi3k-alpha-degrader</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/pivekimab-sunirine-bpdcn-cd123-adc-approval</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/plasma-protein-binding-free-drug-hypothesis</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/posebusters-pose-validation</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/prolif-interaction-fingerprints-pose-analysis</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/protac-oral-bioavailability-beyond-rule-of-five</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/protonation-states-tautomers-docking</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/reactive-metabolites-bioactivation-structural-alerts</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/redocking-rmsd-validating-docking-protocol</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ret-fusion-mutant-cancer-selpercatinib-pralsetinib-landscape</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ros1-fusion-nsclc-tki-landscape</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ros1-g2032r-solvent-front-resistance</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/sonrotoclax-bcl2-inhibitor-mantle-cell-lymphoma</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/t790m-osimertinib-resistance</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/ultra-large-library-virtual-screening</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/vepdegestrant-first-protac-fda-approval-esr1</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/vina-gnina-glide-scoring-function-comparison</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
  <url><loc>https://liganx.com/blog/water-networks-displaceable-waters-docking</loc><lastmod>2026-08-26</lastmod><priority>0.7</priority></url>
</urlset>
